Skip to main content
TB

Turtl.Bio

Turtl.Bio provides a decision‑support platform for pre‑IND biotech teams, turning FDA guidance, ICH clauses, and approval packages into structured, auditable answers for regulatory questions such as whether male‑only drugs require female animal toxicology studies. By capturing key product attributes and applying expert‑validated logic, the tool surfaces relevant precedent and delivers a clear, documented recommendation, reducing reliance on costly consultants.

New York, United StatesFounded 2026250+ followers
Updated 1 month ago

Funding

Funding not disclosed

Funding rounds are not available yet.

Founders

Product

Problem

Pre‑IND biotech teams often lack in‑house regulatory expertise, forcing them to interpret conditional FDA language and ICH clauses manually. This results in time‑consuming searches through PDFs, reliance on costly consultants, and delayed study planning.

Solution

Turtl Bio offers a structured, audit‑ready platform that captures a product’s modality, indication, population, and development stage, then routes the input through expert‑validated decision logic derived from FDA guidance, ICH clauses, and precedent approval documents. The system surfaces comparable approved products and presents a clear, sourced regulatory conclusion—e.g., whether gender‑specific toxicology studies are required. All reasoning steps are traceable, linking each outcome to the specific clause, condition, and comparator that support it. By automating this reasoning layer, Turtl Bio reduces dependence on expensive consultants and accelerates IND‑readiness for small‑molecule and radioligand programs.

Target Audience

Primary users are pre‑IND biotech companies with fewer than 50 employees, typically having 0–1 regulatory hires and seeking cost‑effective, auditable answers to regulatory questions.

Features

  • Structured intake forms that standardize product attributes before any analysis
  • Curated decision paths that encode conditional ICH clauses and FDA guidance
  • Automated precedent matching to FDA review documents for comparable approvals
  • Transparent audit trail linking each regulatory recommendation to its source clause and comparator
  • Subscription pricing model affordable for teams with limited or no dedicated regulatory staff
This profile is AI-generated and may contain inaccuracies.